PE20210125A1 - Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos - Google Patents

Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos

Info

Publication number
PE20210125A1
PE20210125A1 PE2020000380A PE2020000380A PE20210125A1 PE 20210125 A1 PE20210125 A1 PE 20210125A1 PE 2020000380 A PE2020000380 A PE 2020000380A PE 2020000380 A PE2020000380 A PE 2020000380A PE 20210125 A1 PE20210125 A1 PE 20210125A1
Authority
PE
Peru
Prior art keywords
methods
cancer
drug
antibody conjugates
activable antibody
Prior art date
Application number
PE2020000380A
Other languages
English (en)
Inventor
Shweta Singh
Jennifer Hope Richardson
Laura Patterson Serwer
Jonathan Alexander Terrett
Susan E Morgan-Lappe
Tracy Henriques
Sherry L Ralston
Marvin Robert Leanna
Ilaria Badagnani
Sahana Bose
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20210125A1 publication Critical patent/PE20210125A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere en general a anticuerpos activables conjugados que se fijan a CD71 en su forma activa (Formula I, II), a metodos para elaborar y usar estos anticuerpos activables conjugados anti-CD71 en una variedad de indicaciones terapeuticas, de diagnostico y profilacticas. Dichos anticuerpos son utiles contra canceres de tipo cancer gastrico, cancer de ovario, cancer de esofago, cancer de pulmon de celulas no pequenas, cancer de mama ER+, entre otros
PE2020000380A 2017-10-14 2018-10-12 Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos PE20210125A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
PE20210125A1 true PE20210125A1 (es) 2021-01-19

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000380A PE20210125A1 (es) 2017-10-14 2018-10-12 Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos

Country Status (34)

Country Link
US (3) US20190111150A1 (es)
EP (2) EP3834846A1 (es)
JP (2) JP7374891B2 (es)
KR (4) KR20230070046A (es)
CN (1) CN111278467A (es)
AR (1) AR115178A1 (es)
AU (1) AU2018346969A1 (es)
BR (1) BR112020007302B1 (es)
CA (1) CA3077730A1 (es)
CL (1) CL2020000977A1 (es)
CO (1) CO2020005685A2 (es)
CR (1) CR20200206A (es)
CY (1) CY1123968T1 (es)
DK (1) DK3691692T3 (es)
DO (1) DOP2023000150A (es)
EC (1) ECSP20025198A (es)
ES (1) ES2864013T3 (es)
HR (1) HRP20210436T8 (es)
HU (1) HUE054037T2 (es)
IL (1) IL273586A (es)
LT (1) LT3691692T (es)
MA (1) MA50752B1 (es)
MD (1) MD3691692T2 (es)
MX (1) MX2020003723A (es)
PE (1) PE20210125A1 (es)
PL (1) PL3691692T3 (es)
PT (1) PT3691692T (es)
RS (1) RS61596B1 (es)
RU (2) RU2771292C2 (es)
SG (1) SG11202003378WA (es)
SI (1) SI3691692T1 (es)
TW (2) TW202330039A (es)
UY (1) UY37931A (es)
WO (1) WO2019075417A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
LT3292149T (lt) * 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
JP2023520821A (ja) * 2020-04-08 2023-05-19 アリアダ セラピューティクス，インコーポレイテッド 血液脳関門送達のための組成物および方法
WO2021207657A1 (en) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2022388735A1 (en) 2021-11-09 2024-05-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
WO2024026474A1 (en) * 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
EA201692127A1 (ru) * 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
EP2424891B1 (en) * 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Erg monoclonal antibodies
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
RU2636029C2 (ru) * 2011-02-01 2017-11-17 Генмаб А/С Человеческие антитела и конъюгаты антитело-препарат против cd74
TR201819828T4 (tr) * 2012-01-31 2019-01-21 Sbi Biotech Co Ltd Anti-fosfolipaz d4 antikoru.
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
SI3088419T1 (sl) * 2013-12-25 2019-01-31 Daiichi Sankyo Company Zdravilni konjugat anti trop2 protitelesa
LT3292149T (lt) 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用

Also Published As

Publication number Publication date
JP7374891B2 (ja) 2023-11-07
SI3691692T1 (sl) 2021-04-30
HRP20210436T8 (hr) 2022-01-07
RU2020115713A3 (es) 2022-02-25
MA50752A (fr) 2020-08-12
KR102385495B1 (ko) 2022-04-15
MA50752B1 (fr) 2021-03-31
KR20230070046A (ko) 2023-05-19
JP2020537649A (ja) 2020-12-24
BR112020007302A2 (pt) 2020-09-29
CO2020005685A2 (es) 2020-05-15
DOP2023000150A (es) 2023-08-31
KR20230004932A (ko) 2023-01-06
EP3691692B8 (en) 2021-05-26
CL2020000977A1 (es) 2020-09-11
KR102529359B1 (ko) 2023-05-09
WO2019075417A1 (en) 2019-04-18
ECSP20025198A (es) 2020-06-30
RS61596B1 (sr) 2021-04-29
BR112020007302B1 (pt) 2023-01-31
HRP20210436T1 (hr) 2021-04-30
KR20220045088A (ko) 2022-04-12
CR20200206A (es) 2021-02-18
RU2020115713A (ru) 2021-11-16
PL3691692T3 (pl) 2021-07-19
MX2020003723A (es) 2020-07-22
US20210145978A1 (en) 2021-05-20
RU2771292C2 (ru) 2022-04-29
AR115178A1 (es) 2020-12-09
KR20200070324A (ko) 2020-06-17
EP3691692A1 (en) 2020-08-12
CY1123968T1 (el) 2022-05-27
HUE054037T2 (hu) 2021-08-30
RU2022111211A (ru) 2022-05-05
DK3691692T3 (da) 2021-03-22
EP3691692B1 (en) 2020-12-30
TWI780237B (zh) 2022-10-11
JP2024012366A (ja) 2024-01-30
SG11202003378WA (en) 2020-05-28
US20240115724A1 (en) 2024-04-11
CA3077730A1 (en) 2019-04-18
ES2864013T3 (es) 2021-10-13
IL273586A (en) 2020-05-31
MD3691692T2 (ro) 2021-05-31
EP3834846A1 (en) 2021-06-16
AU2018346969A1 (en) 2020-04-23
TW201927815A (zh) 2019-07-16
PT3691692T (pt) 2021-03-29
TW202330039A (zh) 2023-08-01
UY37931A (es) 2019-04-30
US20190111150A1 (en) 2019-04-18
CN111278467A (zh) 2020-06-12
LT3691692T (lt) 2021-05-10

Similar Documents

Publication Publication Date Title
PE20210125A1 (es) Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
UY33591A (es) Nuevas proteínas de unión a antígenos
CY1124402T1 (el) Προϊοντα συζευξης πυρρολοβενζοδιαζεπινης-αντισωματος
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CY1123883T1 (el) Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
CY1121663T1 (el) Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
PE20181953A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
EA201690080A1 (ru) Применение молекул, ингибирующих семафорин-4d, в комбинации с иммуномодулирующей терапией для ингибирования роста и метастазирования опухолей
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
AR080513A1 (es) Moleculas de union cd37 y sus inmunoconjugados
NZ729243A (en) Novel glycan conjugates and use thereof
TN2015000396A1 (en) Antibody drug conjugates
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
MX2011010469A (es) Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
EA201390695A1 (ru) Способы лечения рака
EA201691384A3 (ru) Конструкции варианта sirp-альфа и их применение
CO2020000517A2 (es) Fragmento fab de anticuerpo anti-ceacam5 de humano novedoso
CU24320B1 (es) Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
PE20221830A1 (es) Anticuerpos especificos contra la claudina 18.2 tumoral
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
AR104895A1 (es) Conjugados fluorescentes